Letters to the Editor

Cardiovascular Disease in the Elderly: Comment

Enfermedad cardiovascular en el anciano: comentario

To the Editor,

We have read with interest the review article by Jackson et al. on cardiovascular disease in the elderly. An important conclusion of the article is the lack of scientific support for therapeutic strategies in this population, due to the frequent exclusion of elderly patients from clinical trials. This is a common situation in relation to the different diseases mentioned in the article and, in particular, to myocardial infarction (MI). In the section devoted to this disease, the authors summarize the special features of fibrinolysis (FL) and percutaneous coronary intervention (PCI) in this age group. Following our recent articles on the subject,1,2 we would like to offer several comments.

First, eligibility for reperfusion therapy crucially depends on the temporal stage of MI at the time of presentation, and the risk of complications at baseline. Both these factors are influenced by age.2,3 Delays in presentation increase with age due to the decreased perception of pain, cognitive impairments, comorbidities (“distractors”), or social limitations.4 This delay is strikingly longer in community registries (patients 75 years and older) than in clinical trials (4.7 h vs 2.1 h, respectively).5-7 However, even in the latter case, advanced age is associated with delayed presentation and an increased risk of complications.6

On the other hand, the authors refer to intracranial hemorrhage (ICH) secondary to FL. Although ICH is a catastrophic event, death from other causes remains the most common adverse event in elderly patients with MI; specifically, there is a high rate of electrical and mechanical complications (e.g., free-wall rupture, cardiogenic shock). In an analysis of 706 patients with MI aged 75 years or more, free-wall rupture was more frequent among those treated with FL (17.1%) than in those undergoing PCI (4.9%) and even in those not receiving reperfusion therapy (7.9%).8 In fact, FL could have a deleterious effect on elderly patients. Thus, the management of these patients remains an open question. Lenderink et al.9 demonstrated the usefulness of a group of variables to predict early mortality, most of which are available at the time of admission. These were used to develop and validate a risk model that was especially calibrated for elderly patients and which was proposed as an additional tool with which to choose the best therapeutic approach. However, the final decision continues to be made individually, taking into account the best outcome as well as the most humane choice regarding a serious disease with frequent and fatal complications. Moreover, the principle of patient autonomy (respect for their preferences) should play a role in our decisions; the patients’ wishes not to undergo invasive procedures are specifically mentioned in the clinical practice guidelines.4,5

Amelia Carro,* Rachel Bastiaenen, and Juan Carlos Kaski

Cardiovascular Sciences Research Centre, St. George’s University, London, United Kingdom

*Corresponding author: E-mail address: achevia@gmail.com (A. Carro).

Available online 17 November 2011

REFERENCES


*SEE RELATED ARTICLE:
DOI: 10.1016/j.rec.2011.05.003
doi:10.1016/j.rec.2011.09.007

Undernourishment and Prognosis in Heart Failure

Desnutrición y pronóstico en insuficiencia cardiaca

To the Editor,

We were very interested to read the article by Bonilla-Palomas et al., “Influence of undernourishment on long-term mortality in patients hospitalized for heart failure” (Influencia de la desnutrición NS la mortalidad a largo plazo de pacientes hospitalizados por insuficiencia cardiaca),1 in which the authors analyze nutritional status (NS) and its influence on patient prognosis after acute hospitalization for heart failure (HF). The role of NS in the prognosis for HF has also been studied by our group with a similar follow-up period (median: 26.7 months) in an outpatient context.2 The results from both studies indicate that properly nourished

1885-5857/$ – see front matter © 2011 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.